Robert A Baiocchi
Overview
Explore the profile of Robert A Baiocchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
2986
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coghill A, Van Bibber N, Baiocchi R, Arnold S, Riedlinger G, Schneider B, et al.
Cancer Epidemiol Biomarkers Prev
. 2025 Feb;
PMID: 40019488
Background: People living with HIV (PWH) have improved life expectancy due to effective HIV therapy but still experience immune impairment (e.g., altered CD4/CD8 T-cells). We hypothesized that tumors diagnosed in...
2.
Pray B, Baiocchi E, Leon S, Barta B, Koirala S, Tsyba L, et al.
Blood Adv
. 2025 Feb;
PMID: 40009753
Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma characterized by significant genomic instability. MCL patients who progress on targeted therapies have a short survival; thus, novel therapeutic strategies are...
3.
Brown-Burke F, Saadey R, Mao H, Marra P, Brooks E, Wandtke A, et al.
Blood Adv
. 2025 Jan;
PMID: 39825858
Hemophagocytic lymphohistiocytosis (HLH) is a rare but aggressive and potentially lethal hyperinflammatory syndrome characterized by pathologic immune activation and excessive production of proinflammatory cytokines leading to tissue damage and multisystem...
4.
Lurain K, El Zarif T, Ramaswami R, Nassar A, Adib E, Abdel-Wahab N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
24(12):873.
PMID: 39603773
No abstract available.
5.
Briercheck E, Ravishankar S, Ahmed E, Carias Alvarado C, Barrios Menendez J, Silva O, et al.
Blood Adv
. 2024 May;
8(14):3731-3744.
PMID: 38815238
Epstein-Barr virus (EBV) is a potent carcinogen linked to hematologic and solid malignancies and causes significant global morbidity and mortality. Therapy using allogeneic EBV-specific lymphocytes shows promise in certain populations,...
6.
Gallagher E, Conlin P, Kazmierczak B, Vyas J, Ajijola O, Kontos C, et al.
JCI Insight
. 2024 May;
9(10).
PMID: 38775155
Physician-scientists play a crucial role in advancing medical knowledge and patient care, yet the long periods of time required to complete training may impede expansion of this workforce. We examined...
7.
Annunzio K, Bhatta S, Hanel W, Zhao Q, Owen M, Rosen H, et al.
Hematol Oncol
. 2024 May;
42(3):e3278.
PMID: 38726682
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma. Circulating lymphoma (CL) cells can be seen at diagnosis in some FL patients, however, previous studies evaluating this have...
8.
Lurain K, El Zarif T, Ramaswami R, Nassar A, Adib E, Abdel-Wahab N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(8):523-530.
PMID: 38714474
Background: Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on...
9.
McNally G, Aossey C, Wiczer T, Sinnott L, Lustberg M, Baiocchi R, et al.
Leuk Lymphoma
. 2024 Apr;
65(8):1110-1116.
PMID: 38648546
The frontline immuno-chemotherapy regimen for HIV-associated non-Hodgkin Lymphoma is dose-adjusted EPOCH ± R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). Chemotherapy-induced peripheral neuropathy (CIPN), caused by vincristine, is a common...
10.
Denlinger N, Song N, Zhang X, Jeon H, Peterson C, Wang Y, et al.
Blood Adv
. 2024 Apr;
8(12):3140-3153.
PMID: 38607381
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Robust biomarkers and a complete understanding of CAR T-cell function in the postinfusion phase remain...